Services

Trinity HTA Vision

Nuanced, actionable HTA insights powered by expert analysis and dynamic technology

Home / Services / Evidence, Access & Pricing / Trinity HTA Vision

Digesting and interpreting HTA outcomes—and applying those learnings to day-to-day decision-making—is a complex, ever-changing challenge for Global Market Access leaders in life sciences.

It is not enough to simply know what the decisions are and when they are made—with the landscape continually evolving, analogues and future impact cannot be judged by looking at decisions alone.

Nuanced implications come from expert knowledge of countries/agencies, therapeutic areas (TAs) and lifecycle stage. Context is essential to achieve actionable recommendations for a particular brand—as are quick insights to answer the questions that matter:

How do these developments impact related initiatives: study design, evidence generation planning, licensing or business development?
Is there anything new or different that will set precedent?
What is the competition doing—are there learnings and innovations that will help to drive access?
Are there insights that will help minimize time to access and reimbursement?
What are the broader trends that each decision contributes to?
How can these insights be distilled into digestible tidbits to drive decision-making?
What is the impact on affiliates?

Trinity HTA Vision offers a portfolio of solutions that extract forward-looking, relevant implications—identifying the signal amongst the noise.

Reduce potential blindspots

Stay close to competitive landscape changes and evidence requirements evolution
Understand local nuance
Involve country/regional teams and affiliates

Go beyond the rating

Focus on the value drivers and detractors that power HTA decisions
Democratize insights vs. just the data

Apply learnings and trends

Characterize payer-level attitudes and trends across geographies for core products to enhance predictions of future behaviors
Minimize risks and capitalize on opportunities with a comprehensive understanding of payer decision-making

Trinity HTA Vision
Brochure

Download Now

HTA Vision Strategic Insights

HTA Vision offers custom solutions to provide timely, strategic market access insights and impactful interpretation of payer decisions globally.

Precise insights are curated by experts with deep life sciences commercialization, global HTA and access knowledge

Focus on high-impact business questions and actionable recommendations

Flexible, scalable deliverables are customized for each client’s needs/objectives

Choice of indications/TAs, countries/agencies
Choice of strategic outputs with different views and levels of reporting

Expert team provides partnership in navigating global market access complexities

Workshops and discussion sessions on decisions, implications, trends, challenges and mitigation strategies at the global/local levels
Evidence generation/clinical development planning
Payer decision motivation and market evolution planning, pricing exploration
Education—HTA process and key inflection points by country

Easy-to-use technology keeps stakeholders informed

Real-time automated tracking through AIML
Customizable alerts to keep users up to date on key decisions
HTA tracking dashboard to provide a centralized destination for updates and insights
Intuitive UI, easy navigation, convenient visualizations and easily sharable reports to save time

HTA Vision Outputs

Four primary types of strategic outputs offer multiple levels of HTA decision reporting:

Cloud-based HTA Dashboard: Ongoing capture, analysis and synthesis of HTA decision outcomes and rationales for all products and markets in scope

Flash alerts: HTA decision updates (within 48 hours) for high priority products and markets

HTA decision digests: Summary of completed HTAs and their outcomes
Readout of key events: Meetings at a pre-defined cadence to discuss events and implications

Cross-Functional Clarity & Empowerment
HTA Vision empowers multiple teams—including Global Market Access, Commercial, New Product Planning, Clinical Development and HEOR—with a common base of information to reference internally, build insights and inform strategies. Life sciences executives across the organization are able to:
- Examine the performance of key benchmarks and competitive implications
- Understand comparator needs and payer evidence expectations
- Gather intelligence, including feedback from local teams, to predict agencies’ behavior and its impact on the business
- Understand TA-specific standards and benchmark evolution
- Evaluate payer acceptability of various evidence types
- Determine in- and cross-country decision trends
- Drive better internal engagement between global, regional and local teams
HTA Vision offerings are integrated seamlessly across Trinity’s Competitive Intelligence, Launch Excellence, Value and Evidence Strategy COEs so that inter-related KPIs, findings and strategy are cohesive.
Choice of Countries/Agencies
HTA Vision’s offerings are flexible, allowing clients to craft their desired mix of deliverables, focused on the TAs/indications that matter. Clients are also able to select their choice of countries and agencies:
- EMEA—EU4 (Germany – G-BA, France – HAS CT, Spain – AEMPS, Italy – AIFA), UK (NICE), Sweden (TLV), Poland (AOTMIT), Norway, Saudi Arabia, Turkey, Israel, South Africa, Nigeria
- Americas—Canada (CADTH), Brazil (CONITEC), US (ICER), Mexico, Argentina, Colombia
- APAC—Japan (Chuikyo), Australia (PBAC), Korea, China
- Any other country or agency of interest can be included

Latest Trinity HTA Vision Intelligence

Webinars

HTA Vision—Implications Beyond the Rating

Available On Demand

A number of critical manufacturer activities are informed by understanding health technology assessment (HTA) agency behavior across geographies and therapeutic areas—from pipeline, business development and licensing to launch planning preparation through to lifecycle management strategy. Join Max Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access & Pricing Practice, as he hosts a lively […]

Watch Now

Blog

Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future

Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which are expected to improve patient access while balancing financial healthcare sustainability and overall market […]

Blog

Rise with the Waves: France – Accelerating Pricing and Market Access: Two Policies Shaping Pharma’s Future

Executive Summary The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to innovate its healthcare system. The 2024 PLFSS emphasizes: The direct access scheme is expected […]

If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.